Toxicity, recurrence and survival after adjuvant radiotherapy treatment for FIGO stage I cancer of the endometrium

被引:3
|
作者
Moss, EL
Stevens, A
Gray, L
McConkey, C
Fernando, I
机构
[1] Univ Hosp, Dept Clin Oncol, Birmingham, W Midlands, England
[2] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England
关键词
adjuvant radiotherapy; vaginal vault brachytherapy; endometrial cancer; recurrence; survival; toxicity;
D O I
10.1016/S0936-6555(03)00149-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted a retrospective observational study to determine the rate of toxicity, pattern of tumour recurrence and survival associated with radiotherapy treatment for FIGO stage I cancer of the endometrium. All patients had undergone definitive surgery and had been referred to the oncology department of the University Hospital Birmingham, U.K. Two hundred and forty-five women were included in the study; 228 patients were treated with radiotherapy; 160 had external beam radiation alone; 32 had vaginal vault brachytherapy alone; 36 patients had both modalities; and 17 patients were not given radiotherapy. There were nine cases of Grade 3 and 4 radiation reactions, of which four were acute, four were late and one was acute and late toxicity. The severity of both acute and late radiation effects was significantly associated with the delivery of vault brachytherapy (external beam radiotherapy alone compared with brachytherapy alone (1/158 vs 3/32; P=0.02). Thirty-four patients were diagnosed with tumour recurrence (11 distant, 14 local, 4 patients had both distant and local disease and 5 patients had recurrence diagnosed at the time of death). Patients who received no radiotherapy were at greater risk of local pelvic tumour recurrence (P<0.0001; hazard ratio [HR] 9.6, 95% confidence interval (CI) 3.5-26.3). Vaginal vault brachytherapy had no discernible effect on the pattern of tumour recurrence. Forty-six patients died during the follow-up period, 28 of these were attributable to carcinoma of the endometrium. There was no difference in survival between the four treatment groups (P=0.68). The overall 5-year survival rate in our study group was 89.6% (85.4-93.8%). In a proportional hazards model, tumour grade (HR 2.0 per level [1.25, 3.17]; P=0.004]) and age (HR 1.74 per 10 years [1.12, 2.69]; P=0.01) were the only factors found to have an independent influence on survival. This study suggests that, although pelvic radiation may not alter overall survival, it does reduce the risk of local disease recurrence. In this study population, vaginal vault brachytherapy using a vaginal stock/dobbie showed no additional benefits compared with external beam radiotherapy; it was, however, associated with a higher rate of both acute and late radiation effects. (C) 2003 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:250 / 254
页数:5
相关论文
共 50 条
  • [41] Radiotherapy improves survival in stage I endometrial cancer
    Ahmad, K
    LANCET ONCOLOGY, 2006, 7 (03): : 198 - 198
  • [42] Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study
    Kim, Miseon
    Kwon, Byung Su
    Chang, Ha Kyun
    Lee, Seungmee
    Chang, Suk-Joon
    Choi, Jin Young
    Park, Sang-Yoon
    Lee, Maria
    Ryu, Hee-Sug
    Kim, Yong Beom
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (03)
  • [43] Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients
    Tong, Nora
    Kumar, Aalok
    Gelowitz, Gerald
    Tinker, Anna
    Holloway, Caroline
    Ko, Jenny
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients
    Ko, J. J.
    Gelowitz, G.
    Tinker, A. V.
    Holloway, C.
    Kumar, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] The impact of adjuvant therapy on survival in patients with FIGO Stage IB Grade 3 endometrial cancer
    Garg, G.
    Ali-Fehmi, R.
    Morris, R. T.
    Schwartz, K.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (03) : 422 - 429
  • [46] Survival after recurrence of stage I-III breast, colorectal, or lung cancer
    Hassett, Michael J.
    Uno, Hajime
    Cronin, Angel M.
    Carroll, Nikki M.
    Hornbrook, Mark C.
    Fishman, Paul
    Ritzwoller, Debra P.
    CANCER EPIDEMIOLOGY, 2017, 49 : 186 - 194
  • [47] Adjuvant Vaginal Brachytherapy in the Treatment of Surgically Staged, FIGO Stage I Papillary Serous or Clear Cell Endometrial Cancer
    Jeans, E.
    Breen, W.
    Mullikin, T. C.
    Looker, B.
    Harmsen, W. S.
    Mariani, A.
    Haddock, M. G.
    Petersen, I. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E479 - E479
  • [48] Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors
    Huang, Zhen
    Li, Xue
    Li, Ling
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [49] Adjuvant treatment and recurrence rates of stage II uterine cancer
    Melnikoff, A. K.
    Doo, D. W.
    Montgomery, A. M.
    McGwin, G.
    Arend, R. C.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 176 - 177
  • [50] A RETROSPECTIVE STUDY OF ADJUVANT CHEMOTHERAPY PLUS PELVIC RADIOTHERAPY IN FIGO STAGE II EPITHELIAL OVARIAN CANCER
    Chamoun, J.
    Au-Yeng, G.
    te Marvelde, L.
    Quinn, M.
    Grant, P.
    McNally, O.
    Narayan, K.
    Rischin, D.
    Neesham, D.
    Allen, D.
    Hyde, S.
    Bernshaw, D.
    Khaw, P.
    Mileshkin, L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 175 - 176